Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Atrial Fibrillation

ClinicalTrials.gov lists 3,807 trials for Atrial Fibrillation or a narrower condition beneath it. Abbott Medical Devices has the most among industry and government lead sponsors, with 64.

MeSH D001281 Cardiovascular Diseases C14 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 133 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 236 Phase 4 Phase 4 345 Not applicable Not applicable 1,642 Observational Observational 1,370 Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 13 Phase 2 Phase 2 133 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 236 Phase 4 Phase 4 345 Not applicable Not applicable 1,642 Observational Observational 1,370

Trials per phase (log scale)

2 more sections with rows

3,807 of the 3,807 trials are tagged with Atrial Fibrillation itself; the rest are tagged with a narrower condition beneath it.

Get the Atrial Fibrillation report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Atrial Fibrillation trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 15 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 246

1993: 1 trials (Observational 1) 1995: 3 trials (Observational 2, Phase 3 1) 1998: 4 trials (Observational 3, Phase 3 1) 1999: 6 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 2) 2000: 12 trials (Observational 4, Not applicable 1, Phase 4 3, Phase 3 4) 2001: 10 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 1) 2002: 17 trials (Observational 5, Not applicable 8, Phase 4 2, Phase 3 2) 2003: 24 trials (Observational 2, Not applicable 4, Phase 4 9, Phase 3 6, Phase 2 3) 2004: 32 trials (Observational 7, Not applicable 5, Phase 4 9, Phase 3 8, Phase 2/3 2, Phase 2 1) 2005: 60 trials (Observational 17, Not applicable 13, Phase 4 7, Phase 3 11, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 1) 2006: 53 trials (Observational 9, Not applicable 12, Phase 4 7, Phase 3 14, Phase 2 8, Phase 1 3) 2007: 70 trials (Observational 14, Not applicable 21, Phase 4 14, Phase 3 12, Phase 2 8, Phase 1/2 1) 2008: 78 trials (Observational 16, Not applicable 19, Phase 4 19, Phase 3 11, Phase 2/3 2, Phase 2 9, Phase 1 2) 2009: 93 trials (Observational 29, Not applicable 28, Phase 4 15, Phase 3 13, Phase 2 5, Phase 1/2 1, Phase 1 2) 2010: 98 trials (Observational 28, Not applicable 32, Phase 4 16, Phase 3 13, Phase 2 6, Phase 1 3) 2011: 106 trials (Observational 40, Not applicable 35, Phase 4 15, Phase 3 4, Phase 2 10, Phase 1 2) 2012: 139 trials (Observational 39, Not applicable 57, Phase 4 22, Phase 3 11, Phase 2 8, Phase 1 2) 2013: 138 trials (Observational 56, Not applicable 45, Phase 4 12, Phase 3 15, Phase 2/3 1, Phase 2 8, Phase 1 1) 2014: 173 trials (Observational 73, Not applicable 60, Phase 4 12, Phase 3 13, Phase 2 7, Phase 1/2 2, Phase 1 6) 2015: 186 trials (Observational 73, Not applicable 82, Phase 4 18, Phase 3 7, Phase 2/3 1, Phase 2 1, Phase 1/2 3, Phase 1 1) 2016: 201 trials (Observational 88, Not applicable 78, Phase 4 22, Phase 3 6, Phase 2 4, Phase 1/2 2, Phase 1 1) 2017: 193 trials (Other 1, Observational 85, Not applicable 83, Phase 4 7, Phase 3 8, Phase 2/3 1, Phase 2 4, Phase 1 4) 2018: 219 trials (Other 1, Observational 88, Not applicable 96, Phase 4 18, Phase 3 9, Phase 2/3 2, Phase 2 4, Phase 1/2 1) 2019: 221 trials (Observational 87, Not applicable 97, Phase 4 17, Phase 3 11, Phase 2/3 1, Phase 2 5, Phase 1 3) 2020: 217 trials (Observational 95, Not applicable 100, Phase 4 13, Phase 3 4, Phase 2/3 1, Phase 2 4) 2021: 246 trials (Observational 105, Not applicable 109, Phase 4 18, Phase 3 6, Phase 2 5, Phase 1 3) 2022: 240 trials (Observational 93, Not applicable 120, Phase 4 10, Phase 3 11, Phase 2 4, Phase 1 2) 2023: 235 trials (Observational 85, Not applicable 123, Phase 4 13, Phase 3 9, Phase 2/3 1, Phase 2 1, Phase 1 3) 2024: 237 trials (Observational 80, Not applicable 129, Phase 4 10, Phase 3 7, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 4) 2025: 231 trials (Observational 65, Not applicable 139, Phase 4 12, Phase 3 4, Phase 2/3 1, Phase 2 6, Phase 1 4)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 233
2025 231
2024 237
2023 235
2022 240
2021 246
2020 217
2019 221
2018 219
2017 193

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 270 trials starting in 2026 and about 250 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 375 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 2,116 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Atrial Fibrillation trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 47
Phase 1/2 13
Phase 2 133
Phase 2/3 18
Phase 3 236
Phase 4 345
Not applicable 1,642
Observational 1,370
Expanded access 1
Unknown 2

How many Atrial Fibrillation trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 243
Recruiting 477
Enrolling by invitation 45
Active, not recruiting 174
Completed 1,794

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Atrial Fibrillation trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Abbott Medical Devices 64
Boston Scientific Corporation 62
Bayer 59
Biosense Webster, Inc. 50
Boehringer Ingelheim 45

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Atrial Fibrillation? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Rivaroxaban 91
Edoxaban 43
Dabigatran 42
DRONEDARONE 26
Vernakalant 15

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Warfarin VKA 88
Apixaban IR 67
amiodarone amiodarone 48
EC Aspirin 25
BIBR 1048 low1 25

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Atrial Fibrillation trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 3,274 101
Atrial fibrillation 2,840 79
Cardiac failure 2,495 60
Hospitalization for ischemic or hemorrhagic stroke or systemic embolism or bleeding 1,497 1
Cardiac failure congestive 1,342 57

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Atrial Fibrillation? (5,286)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. The New England journal of medicine 2026 Yes
Operator learning curve with a novel dual-energy lattice-tip ablation system. Heart rhythm 2026 Yes
Catheter-based left atrial appendage CLOSURE in patients with atrial fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial. American heart journal 2026 Yes
Effect of Amiodarone after Catheter Ablation According to Left Atrial Structure and Function: The AMIO-CAT Trial. The American journal of cardiology 2026 Yes
Management of new-onset atrial fibrillation in critically ill patients: A national multicenter prospective cohort. Anaesthesia, critical care & pain medicine 2026 Yes

Showing 5 of 5,286 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages